A breast tumour suppressor role for PPARγ was first demonstrated in vitro when treatment of human MCF-7 and MDA-MB-231 breast cancer cells with PPARγ ligands resulted in decreased cell proliferation, promotion of differentiation, and induction of apoptosis [4,5,10,11]. This evidence concerns the gene PPARG and breast neoplasm.